Mazdutide (IBI362) is a weekly GLP-1 and glucagon receptor dual agonist developed by Innovent Biologics, currently in Phase 3 trials in China. Phase 3 GLORY-1 trial data showed 14.5% body weight reduction over 36 weeks.
GLP-1/Glucagon Dual Agonist
Mazdutide (IBI362) is a weekly GLP-1 and glucagon receptor dual agonist developed by Innovent Biologics, currently in Phase 3 trials in China. Phase 3 GLORY-1 trial data showed 14.5% body weight reduction over 36 weeks.
Research Use Only — not intended for human consumption
Research peptides are sold for laboratory use only and are not intended for human consumption.
Week-by-week dosing, reconstitution steps, supplies checklist, and cycle tips.
Week-by-week dosing protocol1 clinic in our directory offer Mazdutide. Use the button below to find one near you.
Find a Peptide Clinic Near YouArticles about Mazdutide and related topics
Peptide Sciences, the largest grey-market research peptide vendor in the US, voluntarily shut down on March 6, 2026. Here is what happened, why it closed, and what the closure means for researchers and the broader peptide industry.
Looking for where to buy retatrutide for research use? Here’s a supplier checklist (COAs, testing, reviews, red flags) plus the clinical-trial pathway for legitimate access.
The injectable peptides craze is sweeping the US, with many individuals experimenting for various health benefits. Learn the key facts and implications for patients.
MyPeptideMatch.com does not provide medical advice. Always consult a qualified healthcare provider before starting any peptide therapy. Regulatory status may change.